1-beta-d-arabinofuranosyl-(e)-5- (2-halogenovinyl) uracil derivatives
CA 2085994 A1 · Owner: Kano, Fumitaka · Inventors: Kano, Fumitaka; Ijichi, Katsushi; Machida, Haruhiko
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a novel 1-.beta.-Darabinofuranosyl-(E)-5-(2-halogenovinyl)uracil derivative represented by the following formula (I) whose, concentration in blood as XVAU can be kept high for many hours when it is administered orally. The present invention also relates to an antiviral agent comprising as an active ingredient the compound of the present invention. Further the present invention relates to a, method for treating viral diseases which comprises administering to a patient with a viral disease a safe and effective amount of the compound of the present invention. (I), wherein X represents a halogen; and R1 R2 and R3, which, may be the same or different each …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 23, 1992. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 23, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 23, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.